All In Biotech

Drug Trial Radar · NCT05680558

Photopheresis in Early-stage Mycosis Fungoides

THERAKOS® CELLEX Photopheresis System as an Interventional Therapy for the Treatment of Early Stage CTCL (Mycosis Fungoides), an Open-label, Single-arm, Multi-center, Phase II Study

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

74

Planned (sponsor's estimate)

Start

May 8, 2021

Primary completion

Mar 2027

Study completion Jul 2028

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Mallinckrodt
First posted
Jan 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that patients with early stage CTCL may have markers in their blood which were previously observed primarily in late stage disease, such as clonal T cell populations. Considering these findings, the study aims to investigate whether photopheresis therapy may be used earlier in the disease course to produce a clinical response.

Conditions

  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides

Interventions

  • UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX PhotopheresisDrug

    Extracorporeal Photopheresis (ECP)

  • THERAKOS® CELLEX photopheresis systemDevice

    THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: 1 Year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.